2018 Market Spotlight: Norovirus – Key Pipeline Drugs, Clinical Trials, Probability of Success, Key Upcoming Events, and an Epidemiological Overview – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Norovirus” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Norovirus market, comprising key
pipeline drugs, clinical trials, probability of success, key upcoming
events, and an epidemiological overview.

Key Takeaways

• Worldwide, about one out of every five cases of acute gastroenteritis
  is associated with norovirus. Norovirus is responsible for
  approximately 685 million cases of gastroenteritis every year.
• Globally, norovirus is estimated to cause approximately 200,000 deaths
  annually, with at least 50,000 being children, mainly in developing
  countries.
• There are four clinical candidates in development for norovirus; two
  in Phase I and two in Phase II. The majority of clinical candidates
  currently in the pipeline for norovirus are vaccines. These are
  administered via the oral, intranasal, and intramuscular routes.
• Topline Phase IIb trial results for Monovalent Norovirus VLP Vaccine
  is the only high-impact upcoming event for drugs in the norovirus
  space.
• The overall likelihood of approval of a Phase I antiviral asset is
  16.2%, and the average probability a drug advances from Phase III is
  75.9%. Drugs, on average, take 8.6 years from Phase I to approval,
  compared to 9 years in the overall infectious disease space.
• The clinical trials distribution across Phase I-III indicates that the
  vast majority of trials for norovirus have been in the early and
  mid-phases of development, with 91% of trials in Phase I-II, and only
  9% in Phase III.
• Takeda has the highest number of completed and planned clinical trials
  for norovirus, with eight trials in each category. Takeda also leads
  industry sponsors with by far the highest overall number of clinical
  trials for norovirus, followed by Vaxart.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

Norovirus outbreaks

Challenges for vaccine development

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

Figure 1: Overview of pipeline drugs for norovirus in the US

Figure 2: Pipeline drugs for norovirus, by company

Figure 3: Pipeline drugs for norovirus, by drug type

Figure 4: Pipeline drugs for norovirus, by classification

Figure 5: Key upcoming events in norovirus

Figure 6: Probability of success in the norovirus pipeline

Figure 7: Clinical trials in norovirus

Figure 8: Top 10 drugs for clinical trials in norovirus

Figure 9: Top 10 companies for clinical trials in norovirus

Figure 10: Norovirus trials status

Figure 11: Norovirus trials sponsors, by phase

LIST OF TABLES

Table 1: Pipeline drugs for norovirus in the US

For more information about this report visit https://www.researchandmarkets.com/r/yf3qp4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs